Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GERN 
Geron Corporation (GERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GERN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.62
1 Year Target Price $3.62
| 4 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.19% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 912.36M USD | Price to earnings Ratio - | 1Y Target Price 3.62 |
Price to earnings Ratio - | 1Y Target Price 3.62 | ||
Volume (30-day avg) 9 | Beta 0.73 | 52 Weeks Range 1.09 - 4.83 | Updated Date 08/28/2025 |
52 Weeks Range 1.09 - 4.83 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.03 | Actual -0.02 |
Profitability
Profit Margin -53.52% | Operating Margin (TTM) -25.4% |
Management Effectiveness
Return on Assets (TTM) -9.63% | Return on Equity (TTM) -31.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 646226414 | Price to Sales(TTM) 5.55 |
Enterprise Value 646226414 | Price to Sales(TTM) 5.55 | ||
Enterprise Value to Revenue 3.93 | Enterprise Value to EBITDA -9.06 | Shares Outstanding 638017024 | Shares Floating 534077712 |
Shares Outstanding 638017024 | Shares Floating 534077712 | ||
Percent Insiders 0.09 | Percent Institutions 81.97 |
Upturn AI SWOT
Geron Corporation
Company Overview
History and Background
Geron Corporation, founded in 1990, is a biopharmaceutical company focused on developing therapies for hematologic malignancies. Initially focused on telomerase inhibitors, it shifted towards hematology after clinical trial setbacks.
Core Business Areas
- Hematologic Malignancies: Focuses on the development and commercialization of therapies for blood cancers, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotechnology industries. The organizational structure is typical of a biotech company, with research, development, and commercial operations divisions.
Top Products and Market Share
Key Offerings
- Rytelo (imetelstat): Rytelo is a telomerase inhibitor being developed for the treatment of lower-risk myelodysplastic syndromes (LR-MDS). Competitors include other treatments for MDS such as Revlimid (Celgene/Bristol Myers Squibb) and Vidaza (Celgene/Bristol Myers Squibb). Market share is pending market launch and penetration. Sales estimates will vary based on commercial success.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. The market for hematologic malignancies is growing due to aging populations and advancements in treatment options.
Positioning
Geron is positioned as a company specializing in hematologic malignancies, specifically targeting LR-MDS with Rytelo. Their competitive advantage lies in the novel mechanism of action of imetelstat.
Total Addressable Market (TAM)
The TAM for LR-MDS is estimated to be several billion dollars. Geron is positioned to capture a significant portion of this market if Rytelo is successful.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action (telomerase inhibition)
- Targeted therapy for LR-MDS
- Strong intellectual property position
- Experienced management team
Weaknesses
- Reliance on a single product candidate (Rytelo)
- History of clinical trial setbacks
- Limited commercialization experience
- High cash burn rate
Opportunities
- Expansion of Rytelo to other indications (e.g., AML)
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Market growth in hematologic malignancies
Threats
- Competition from existing therapies
- Regulatory hurdles and delays
- Clinical trial failures
- Patent challenges
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BMY
- MRTX
- AZN
Competitive Landscape
Geron faces competition from established therapies and companies in the hematologic malignancies space. Success depends on Rytelo's efficacy and differentiation.
Growth Trajectory and Initiatives
Historical Growth: Geron's growth has been largely dependent on clinical trial progress and funding rounds.
Future Projections: Future growth is contingent on the successful commercialization of Rytelo and expansion into other indications. Analyst projections vary widely based on assumptions about clinical trial outcomes and market penetration.
Recent Initiatives: Focusing on the launch of Rytelo and advancing ongoing clinical trials.
Summary
Geron is a clinical-stage biopharmaceutical company with a focus on hematologic malignancies. Its future is highly dependent on the successful commercialization of Rytelo. The company faces competition from established therapies and the inherent risks associated with clinical development, needing to successfully navigate commercialization and potential expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Geron Corporation Investor Relations
- Analyst Reports
- Industry Publications
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Geron Corporation
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 1996-06-30 | CEO, President & Director Mr. Harout Semerjian | ||
Sector Healthcare | Industry Biotechnology | Full time employees 229 | Website https://www.geron.com |
Full time employees 229 | Website https://www.geron.com | ||
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.